This stock will only go up from here. With the $15 million milestone payment yesterday ARQL is one of the best financed bio's out there so there is absolutely no threat on dilution for this year into early next year. CLSN failure yesterday takes out some competition and will only lead investors to ARQL has they look for a play geared toward primary liver cancer. Will the trial succeed? At this price point, who cares. We will have at least doubled our money as this trial progresses.